MDxHealth SA - Company Profile
Powered by 
All the sales intelligence you need on MDxHealth SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MDxHealth SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MDxHealth SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MDxHealth SA (MDxHealth) develops and commercializes advanced epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. The company’s product portfolio includes ConfirmMDx, an epigenetic assay that detects the epigenetic effect of cancer, and SelectMDx, a liquid biopsy assay for prostate cancer. MdxHealth tests are based on MSP (Methylation-Specific polymerase chain reaction) technology, a proprietary DNA-based platform. It also offers biomarker development services to many pharmaceutical companies. MDxHealth markets its products through sales forces, partnerships and distributors. The company has operations in the Netherlands, Belgium and the US. MDxHealth is headquartered in Herstal, Liege, Belgium.
Headquarters
Belgium
Address
Cap Business Center, Rue D'Abhooz 31, Herstal, 4040
Website
mdxhealth.com
Telephone
32 4 3642070
No of Employees
312
Industry
Medical Equipment
Ticker Symbol & Exchange
MDXH (NASD)
Revenue (2025)
$107.9M
19.8%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
12%
(2025 vs 2024)
Market Cap*
$24.5M
Net Profit Margin (2025)
XYZ
26.5%
(2025 vs 2024)
* As of and is in US$
MDxHealth SA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| ConfirmMDx - Prostate Cancer | Biomarker Discovery Services | ConfirmMDx |
| SelectMDx - Prostate Cancer | Development of Companion Diagnostics | SelectMDx |
| Technology: | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In September, the company acquired Exosome Diagnostics from Bio-Techne Corporation. |
| 2025 | Contracts/Agreements | In August, the company signed an agreement to acquire the ExoDx business from Bio-Techne Corporation, a biotech company. |
| 2024 | New Products/Services | In March, the company announced the launch of a non-invasive genetic prostate cancer test. |
Competitor Comparison
| Key Parameters | MDxHealth SA | Myriad Genetics Inc | OPKO Health Inc | Agendia NV | Beckman Coulter Inc |
|---|---|---|---|---|---|
| Headquarters | Belgium | United States of America | United States of America | Netherlands | United States of America |
| City | Herstal | Salt Lake | Miami | Amsterdam | Brea |
| State/Province | - | Utah | Florida | Noord-Holland | California |
| No. of Employees | 312 | 2,700 | 2,275 | - | 11,000 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Koen Hoffman | Chairman | Executive Board | 2018 | 56 |
| Michael K. McGarrity | Director; Chief Executive Officer | Executive Board | 2019 | 62 |
| Ron Kalfus | Chief Financial Officer | Senior Management | 2019 | 50 |
| John Bellano | Chief Commercial Officer | Senior Management | 2019 | 56 |
| Scott McMahan | Chief Financial Officer; Vice President- Finance | Senior Management | - | 74 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer